Results 211 to 220 of about 61,634 (258)

Dopamine and dopamine receptor agonists in cardiovascular therapy

Critical Care Medicine, 1990
Dopamine (DA)--previously regarded simply as the precursor of norepinephrine--is now known to have its own unique effects on cardiovascular regulation which are mediated, in part, by activating specific DA receptors. DA has long been used in the treatment of shock and heart failure.
M B, Murphy, W J, Elliott
openaire   +2 more sources

Dopamine agonists in Parkinson's disease

Neurology, 1995
The main pathologic hallmark of Parkinson's disease is a degeneration of the dopaminergic cells in the substantia nigra, pars compacta and--to a lesser extent--in the ventral tegmental area. Striatal dopamine concentrations are significantly reduced before clinical symptoms become apparent.
E C, Wolters, G, Tissingh, P L, Bergmans, M A, Kuiper   +3 more
openaire   +2 more sources

Treatment of Acromegaly with Dopamine Agonists

Endocrinology and Metabolism Clinics of North America, 1992
This article reviews the current understanding of how dopamine agonists stimulate growth hormone secretion in normal individuals, yet suppress growth hormone secretion in acromegaly patients. Although bromocriptine normalizes growth hormone or somatomedin C hypersecretion in a minority of patients, a significant number of subjects have a clinical ...
C A, Jaffe, A L, Barkan
openaire   +2 more sources

Dopamine agonist‐responsive depression

Psychogeriatrics, 2013
AbstractDopaminergic dysfunction is implicated in the pathophysiology of treatment‐resistant depression. In this review, we describe the putative role of dopamine in depression, summarize the evidence for the efficacy of dopamine receptor agonists in the treatment of treatment‐resistant depression, and discuss the underlying mechanisms by which these ...
Hiroaki, Hori, Hiroshi, Kunugi
openaire   +2 more sources

Dopamine agonist action of phencyclidine

Synapse, 2005
AbstractAlthough the psychotomimetic action of phencyclidine is often used to model a hypoglutamate theory of psychosis or schizophrenia, work also exists showing that phencyclidine has a significant affinity for the dopamine D2 receptor. The present study was done to determine whether phencyclidine has a direct functional dopamine‐like action on cells.
Philip, Seeman, Mercedes, Lasaga
openaire   +2 more sources

Dopamine agonists and Parkinson's disease

Clinical Neurology and Neurosurgery, 1984
The therapeutic use of dopamine agonists for Parkinson's disease, clinical guidelines for their introduction into antiparkinson regimens, and their range of adverse effects are reviewed. The role played by the dopaminomimetic ergots in elucidating dopamine receptor function, and laboratory methods that identify dopamine agonists, are also examined.
K, Burton, D B, Calne
openaire   +2 more sources

Alopecia induced by dopamine agonists

Neurology, 2002
We report two women with PD who developed alopecia while being treated with the dopamine agonists pramipexole and ropinirole. The alopecia reversed partially after the drugs were discontinued. Both women were postmenopausal and had no history of hair loss or other dermatologic disorders.
Rowena E, Tabamo, Alessandro, Di Rocco
openaire   +2 more sources

Ropinirole hydrochloride, a dopamine agonist

Acta Crystallographica Section C Crystal Structure Communications, 2006
Ropinirole hydrochloride, or diethyl[2-(2-oxo-2,3-dihydro-1H-indol-4-yl)ethyl]ammonium chloride, C16H25N2O+.Cl-, belongs to a class of new non-ergoline dopamine agonists which bind specifically to D2-like receptors with a selectivity similar to that of dopamine (D3 > D2 > D4).
Krishnan, Ravikumar, Balasubramanian, Sridhar   +1 more
openaire   +2 more sources

Switching and combining of dopamine agonists

Journal of Neurology, 2004
Dopamine agonists have been proved safe and effective as initial therapy in early stages of Parkinson's disease. Prospective long-term clinical trials demonstrated that initial symptomatic treatment with a dopamine agonist is associated with a significantly reduced risk for motor complications in comparison with levodopa therapy.
Susann, Junghanns, Theresa, Glöckler, Heinz, Reichmann   +2 more
openaire   +2 more sources

Switching and combining dopamine agonists

Journal of Neural Transmission, 2003
Switching from one dopamine agonist to another is common practice in the treatment of patients with Parkinson's disease. This paper describes some ideas on the most practical way to perform switching. In addition, it describes the possibilities of combining various dopamine agonists and discusses pros and cons for doing so.
H, Reichmann, B, Herting, A, Mïller, U, Sommer   +3 more
openaire   +2 more sources